buspirone has been researched along with Parkinsonian Disorders in 7 studies
Buspirone: An anxiolytic agent and serotonin receptor agonist belonging to the azaspirodecanedione class of compounds. Its structure is unrelated to those of the BENZODIAZAPINES, but it has an efficacy comparable to DIAZEPAM.
buspirone : An azaspiro compound that is 8-azaspiro[4.5]decane-7,9-dione substituted at the nitrogen atom by a 4-(piperazin-1-yl)butyl group which in turn is substituted by a pyrimidin-2-yl group at the N(4) position.
Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "or s." | 5.72 | The selective 5-HT 1A receptor agonist, NLX-112, overcomes tetrabenazine-induced catalepsy and depression-like behavior in the rat. ( Depoortere, R; Jastrzębska-Więsek, M; Kołaczkowski, M; Newman-Tancredi, A; Varney, MA; Wesołowska, A, 2022) |
| "or s." | 1.72 | The selective 5-HT 1A receptor agonist, NLX-112, overcomes tetrabenazine-induced catalepsy and depression-like behavior in the rat. ( Depoortere, R; Jastrzębska-Więsek, M; Kołaczkowski, M; Newman-Tancredi, A; Varney, MA; Wesołowska, A, 2022) |
| " In this study we investigated the effect of chronic administration of buspirone and fluoxetine on cerebrospinal fluid (CSF) levels of inflammatory cytokines, TNF-α, IL-1β and IL-6 in 6-hydroxydopamine (6-OHDA)-lesioned rats." | 1.42 | Effect of Chronic Administration of Buspirone and Fluoxetine on Inflammatory Cytokines in 6-Hydroxydopamine-lesioned Rats. ( Farajnia, S; Haddadi, R; Nayebi, AM; Sharifi, H, 2015) |
| "Catalepsy was induced by the unilateral infusion of 6-OHDA (8 μg/2 μl/rat) into the central region of the SNc." | 1.37 | Buspirone improves the anti-cataleptic effect of levodopa in 6-hydroxydopamine-lesioned rats. ( Babapour, V; Mahmoudi, J; Nayebi, AM; Reyhani-Rad, S; Samini, M, 2011) |
| "Buspirone was decreased to 15 mg 3 times daily, ritonavir/indinavir was discontinued, and amprenavir 1200 mg twice daily was added." | 1.32 | Pseudo-Parkinson disease secondary to ritonavir-buspirone interaction. ( Adams, MM; Clay, PG, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Jastrzębska-Więsek, M | 1 |
| Wesołowska, A | 1 |
| Kołaczkowski, M | 1 |
| Varney, MA | 1 |
| Newman-Tancredi, A | 1 |
| Depoortere, R | 1 |
| Shin, E | 1 |
| Lisci, C | 1 |
| Tronci, E | 1 |
| Fidalgo, C | 1 |
| Stancampiano, R | 1 |
| Björklund, A | 1 |
| Carta, M | 2 |
| Azkona, G | 1 |
| Sagarduy, A | 1 |
| Aristieta, A | 1 |
| Vazquez, N | 1 |
| Zubillaga, V | 1 |
| Ruíz-Ortega, JA | 1 |
| Pérez-Navarro, E | 1 |
| Ugedo, L | 1 |
| Sánchez-Pernaute, R | 1 |
| Sharifi, H | 1 |
| Nayebi, AM | 2 |
| Farajnia, S | 1 |
| Haddadi, R | 1 |
| Mahmoudi, J | 1 |
| Samini, M | 1 |
| Reyhani-Rad, S | 1 |
| Babapour, V | 1 |
| Clay, PG | 1 |
| Adams, MM | 1 |
| Lundblad, M | 1 |
| Usiello, A | 1 |
| Håkansson, K | 1 |
| Fisone, G | 1 |
| Cenci, MA | 1 |
7 other studies available for buspirone and Parkinsonian Disorders
| Article | Year |
|---|---|
The selective 5-HT 1A receptor agonist, NLX-112, overcomes tetrabenazine-induced catalepsy and depression-like behavior in the rat.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antidepressive Agents; Buspirone; Catalepsy; Depres | 2022 |
The anti-dyskinetic effect of dopamine receptor blockade is enhanced in parkinsonian rats following dopamine neuron transplantation.
Topics: Amphetamine; Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Benzazepines; Buspirone; Disease | 2014 |
Buspirone anti-dyskinetic effect is correlated with temporal normalization of dysregulated striatal DRD1 signalling in L-DOPA-treated rats.
Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Buspirone; Corpus Striatum; Cyclic AMP Respon | 2014 |
Effect of Chronic Administration of Buspirone and Fluoxetine on Inflammatory Cytokines in 6-Hydroxydopamine-lesioned Rats.
Topics: Animals; Buspirone; Cerebrospinal Fluid; Fluoxetine; Interleukin-1beta; Interleukin-6; Male; Oxidopa | 2015 |
Buspirone improves the anti-cataleptic effect of levodopa in 6-hydroxydopamine-lesioned rats.
Topics: Animals; Antiparkinson Agents; Buspirone; Catalepsy; Dose-Response Relationship, Drug; Injections, I | 2011 |
Pseudo-Parkinson disease secondary to ritonavir-buspirone interaction.
Topics: Buspirone; Drug Interactions; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Pa | 2003 |
Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
Topics: Adenosine A2 Receptor Agonists; Adrenergic Agents; Amantadine; Animals; Antiparkinson Agents; Basal | 2005 |